华中科技大学学报（医学版） ›› 2026, Vol. 55 ›› Issue (5): 742-751.doi: 10.3870/j.issn.1672-0741.25.11.006
陈丹妮, 向菲△
收稿日期:2025-11-06
发布日期:2026-10-30
通讯作者:
△E-mail：2006XH0855@hust.edu.cn
作者简介:陈丹妮,女,2000年生,硕士研究生,E-mail：chendn0012@163.com
基金资助:Chen Danni, Xiang Fei△
Received:2025-11-06
Published:2026-10-30
Contact:
△E-mail：2006XH0855@hust.edu.cn
摘要： 进展性肺纤维化（progressive pulmonary fibrosis,PPF）是指一组表现为进行性恶化表型的间质性肺疾病（interstitial lung disease,ILD）,预后极差。其基于症状、肺功能及影像学进行综合判定,不局限于特定病因,而是涵盖除特发性肺纤维化外所有表现为进行性纤维化的ILD患者。目前识别具有进展风险的早期患者并进行及时干预仍存在困难,现有抗纤维化治疗仅能减缓病情进展而非逆转疾病,且部分患者耐受性不佳。基于此,该文对PPF的发病机制、临床识别、治疗方式等进行综述,旨在为未来PPF患者的早期预测及精准靶向治疗提供新的见解。
中图分类号:
陈丹妮, 向菲. 进展性肺纤维化的研究进展*[J]. 华中科技大学学报（医学版）, 2026, 55(5): 742-751.
Chen Danni, Xiang Fei. Research Progress in Progressive Pulmonary Fibrosis[J]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong, 2026, 55(5): 742-751.
| [1] Raghu G,Remy-Jardin M,Richeldi L,et al.Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults:An official ATS/ERS/JRS/ALAT clinical practice guideline[J].Am J Respir Crit Care Med,2022,205(9):e18-e47. [2] Spagnolo P,Kropski J A,Jones M G,et al.Idiopathic pulmonary fibrosis:Disease mechanisms and drug development[J].Pharmacol Ther,2021,222:107798. [3] Gandhi S,Tonelli R,Murray M,et al.Environmental causes of idiopathic pulmonary fibrosis[J].Int J Mol Sci,2023,24(22):16481. [4] Zhang Y,Huang W,Zheng Z,et al.Cigarette smoke-inac-tivated SIRT1 promotes autophagy-dependent senescence of alveolar epithelial type 2 cells to induce pulmonary fibrosis[J].Free Radic Biol Med,2021,166:116-127. [5] Chen L,Sun R,Lei C,et al.Alcohol-mediated susceptibility to lung fibrosis is associated with group 2 innate lymphoid cells in mice[J].Front Immunol,2023,14:1178498. [6] Leuschner G,Klotsche J,Kreuter M,et al.Idiopathic pulmonary fibrosis in elderly patients:Analysis of the INSIGHTS-IPF observational study[J].Front Med,2020,7:601279. [7] Ruaro B,Pozzan R,Confalonieri P,et al.Gastroesophageal reflux disease in idiopathic pulmonary fibrosis:Viewer or actor? To treat or not to treat?[J].Pharmaceuticals,2022,15(8):1033. [8] Huang W J,Tang X X.Virus infection induced pulmonary fibrosis[J].J Transl Med,2021,19(1):496. [9] Liu G Y,Budinger G R S,Dematte J E.Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis[J].BMJ,2022,377:e066354. [10] Sullivan D I,Jiang M,Hinchie A M,et al.Transcriptional and proteomic characterization of telomere-induced senescence in a human alveolar epithelial cell line[J].Front Med,2021,8:600626. [11] Tirelli C,Pesenti C,Miozzo M,et al.The genetic and epigenetic footprint in idiopathic pulmonary fibrosis and familial pulmonary fibrosis:A state-of-the-art review[J].Diagnostics (Basel),2022,12(12):3107. [12] Moll M,Peljto A L,Kim J S,et al.A polygenic risk score for idiopathic pulmonary fibrosis and interstitial lung abnormalities[J].Am J Respir Crit Care Med,2023,208(7):791-801. [13] Helling B A,Gerber A N,Kadiyala V,et al.Regulation of MUC5B expression in idiopathic pulmonary fibrosis[J].Am J Respir Cell Mol Biol,2017,57(1):91-99. [14] Garcia C K.Idiopathic pulmonary fibrosis:Update on genetic discoveries[J].Proc Am Thorac Soc,2011,8(2):158-162. [15] Oldham J M,Ma S F,Martinez F J,et al.TOLLIP,MUC5B,and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis[J].Am J Respir Crit Care Med,2015,192(12):1475-1482. [16] Singh P,Edjah S,Shi W,et al.Emerging concepts in fibroblast biology and progressive pulmonary fibrosis[J].Semin Respir Crit Care Med,2025,46(4):322-329. [17] Hecker L,Logsdon N J,Kurundkar D,et al.Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance[J].Sci Transl Med,2014,6(231):231ra47. [18] Wynes M W,Edelman B L,Kostyk A G,et al.Increased cell surface Fas expression is necessary and sufficient to sensitize lung fibroblasts to Fas ligation-induced apoptosis:Implications for fibroblast accumulation in idiopathic pulmonary fibrosis[J].J Immunol,2011,187(1):527-537. [19] Ajayi I O,Sisson T H,Higgins P D,et al.X-linked inhibitor of apoptosis regulates lung fibroblast resistance to Fas-mediated apoptosis[J].Am J Respir Cell Mol Biol,2013,49(1):86-95. [20] Zhou Y,Huang X,Hecker L,et al.Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis[J].J Clin Invest,2013,123(3):1096-1108. [21] Bamberg A,Redente E F,Groshong S D,et al.Protein tyrosine phosphatase-N13 promotes myofibroblast resistance to apoptosis in idiopathic pulmonary fibrosis[J].Am J Respir Crit Care Med,2018,198(7):914-927. [22] Golan-Gerstl R,Wallach-Dayan S B,Zisman P,et al.Cellular FLICE-like inhibitory protein deviates myofibroblast fas-induced apoptosis toward proliferation during lung fibrosis[J].Am J Respir Cell Mol Biol,2012,47(3):271-279. [23] Redente E F,Chakraborty S,Sajuthi S,et al.Loss of Fas signaling in fibroblasts impairs homeostatic fibrosis resolution and promotes persistent pulmonary fibrosis[J].JCI Insight,2020,6(1):e141618. [24] Hanson K M,Hernady E B,Reed C K,et al.Apoptosis resistance in fibroblasts precedes progressive scarring in pulmonary fibrosis and is partially mediated by toll-like receptor 4 activation[J].Toxicol Sci,2019,170(2):489-498. [25] Ediga H H,Vemulapalli C P,Sontake V,et al.Wilms tumor 1 impairs apoptotic clearance of fibroblasts in distal fibrotic lung lesions[J].J Clin Investig,2025,135(15):e188819. [26] Luis-García E R,Becerril C,Salgado-Aguayo A,et al.Mitochondrial dysfunction and alterations in mitochondrial permeability transition pore (mPTP) contribute to apoptosis resistance in idiopathic pulmonary fibrosis fibroblasts[J].Int J Mol Sci,2021,22(15):7870. [27] Lin Y,Xu Z.Fibroblast senescence in idiopathic pulmonary fibrosis[J].Front Cell Dev Biol,2020,8:593283. [28] Álvarez D,Cárdenes N,Sellarés J,et al.IPF lung fibroblasts have a senescent phenotype[J].Am J Physiol Lung Cell Mol Physiol,2017,313(6):L1164-L1173. [29] Schafer M J,White T A,Iijima K,et al.Cellular senescence mediates fibrotic pulmonary disease[J].Nat Commun,2017,8:14532. [30] Han D,Gong H,Wei Y,et al.Hesperidin inhibits lung fibroblast senescence via IL-6/STAT3 signaling pathway to suppress pulmonary fibrosis[J].Phytomedicine,2023,112:154680. [31] Zhou S,Peng L,Wang Y,et al.Bazibushen attenuates fibroblast senescence in silica-induced pulmonary fibrosis via FOXO1/PINK1/Parkin Axis[J].Phytomedicine,2025,141:156714. [32] Sanders Y Y,Liu H,Zhang X,et al.Histone modifications in senescence-associated resistance to apoptosis by oxidative stress[J].Redox Biol,2013,1(1):8-16. [33] Blokland K E C,Waters D W,Schuliga M,et al.Senescence of IPF lung fibroblasts disrupt alveolar epithelial cell proliferation and promote migration in wound healing[J].Pharmaceutics,2020,12(4):389. [34] Hernandez-Gonzalez F,Prats N,Ramponi V,et al.Human senescent fibroblasts trigger progressive lung fibrosis in mice[J].Aging,2023,15(14):6641-6657. [35] Rana T,Jiang C,Liu G,et al.PAI-1 regulation of TGF-β1-induced alveolar type Ⅱ cell senescence,SASP secretion,and SASP-mediated activation of alveolar macrophages[J].Am J Respir Cell Mol Biol,2020,62(3):319-330. [36] Probst C K,Montesi S B,Medoff B D,et al.Vascular permeability in the fibrotic lung[J].Eur Respir J,2020,56(1):1900100. [37] Caporarello N,Meridew J A,Aravamudhan A,et al.Vascular dysfunction in aged mice contributes to persistent lung fibrosis[J].Aging Cell,2020,19(8):e13196. [38] Gaikwad A V,Lu W,Dey S,et al.Endothelial-to-mes-enchymal transition:A precursor to pulmonary arterial remodelling in patients with idiopathic pulmonary fibrosis[J].ERJ Open Res,2023,9(2):00487-02022. [39] Zhou J,Xia X,An X,et al.New perspectives on the progression of pulmonary fibrosis:The cascade from aberrant microvascular endothelial cell activation to fibrosis[J].Front Med,2025,12:1639043. [40] Panda B,Chilvery S,Devi P,et al.Inhibition of peptidyl arginine deiminase-4 ameliorated pulmonary fibrosis via modulating M1/M2 polarisation of macrophages[J].Life Sci,2025,362:123354. [41] Li S,Xu H,Liu S,et al.Targeting Lp-PLA2 inhibits profibrotic monocyte-derived macrophages in silicosis through restoring cardiolipin-mediated mitophagy[J].Cell Mol Immunol,2025,22(7):776-790. [42] Crowley L E,Stockley R A,Thickett D R,et al.Neutrophil dynamics in pulmonary fibrosis:Pathophysiological and therapeutic perspectives[J].Eur Respir Rev,2024,33(174):240139. [43] Suzuki M,Ikari J,Anazawa R,et al.PAD4 deficiency improves bleomycin-induced neutrophil extracellular traps and fibrosis in mouse lung[J].Am J Respir Cell Mol Biol,2020,63(6):806-818. [44] Huaux F.Interpreting immunoregulation in lung fibrosis:A new branch of the immune model[J].Front Immunol,2021,12:690375. [45] Kamiya M,Carter H,Espindola M S,et al.Immune mechanisms in fibrotic interstitial lung disease[J].Cell,2024,187(14):3506-3530. [46] Tsukui T,Wolters P J,Sheppard D.Alveolar fibroblast lineage orchestrates lung inflammation and fibrosis[J].Nature,2024,631(8021):627-634. [47] Ganzleben I,Medoff B D.Mechanobiology and the extracellular matrix in pulmonary fibrosis[J].iScience,2025,28(12):113993. [48] Liu F,Lagares D,Choi K M,et al.Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis[J].Am J Physiol Lung Cell Mol Physiol,2015,308(4):L344-L357. [49] Yang J,Ma Y,Zhang R,et al.Fibrotic extracellular matrix microenvironment induces alveolar type Ⅱ epithelial cell senescence via integrin-β1/FAK/YAP signaling pathway[J].Int Immunopharmacol,2025,162:115169. [50] Parimon T,Yao C,Stripp B R,et al.Alveolar epithelial type Ⅱ cells as drivers of lung fibrosis in idiopathic pulmonary fibrosis[J].Int J Mol Sci,2020,21(7):2269. [51] Cohen M L,Brumwell A N,Ho T C,et al.A fibroblast-dependent TGF-β1/sFRP2 noncanonical Wnt signaling axis promotes epithelial metaplasia in idiopathic pulmonary fibrosis[J].J Clin Invest,2024,134(18):e174598. [52] Liang D,Wang Y,Zhu Z,et al.BMP-7 attenuated silica-induced pulmonary fibrosis through modulation of the balance between TGF-β/Smad and BMP-7/Smad signaling pathway[J].Chem Biol Interact,2016,243:72-81. [53] Ramos C,Becerril C,Montaño M,et al.FGF-1 reverts epithelial-mesenchymal transition induced by TGF-β1 through MAPK/ERK kinase pathway[J].Am J Physiol Lung Cell Mol Physiol,2010,299(2):L222-L231. [54] Ong C H,Tham C L,Harith H H,et al.TGF-β-induced fibrosis:A review on the underlying mechanism and potential therapeutic strategies[J].Eur J Pharmacol,2021,911:174510. [55] Klingberg F,Hinz B,White E S.The myofibroblast matrix:Implications for tissue repair and fibrosis[J].J Pathol,2013,229(2):298-309. [56] Cen Z,Cen T,Ding Q,et al.Outcomes and predictors of progression in progressive pulmonary fibrosis[J].Ann Med,2024,56(1):2406439. [57] Ghuman A,Khanna D,Lin C J F,et al.Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort[J].Rheumatology (Oxford),2024,63(2):472-481. [58] Chan C,Ryerson C J,Dunne J V,et al.Demographic and clinical predictors of progression and mortality in connective tissue disease-associated interstitial lung disease:A retrospective cohort study[J].BMC Pulm Med,2019,19(1):192. [59] Mira-Avendano I,Kaye M.Key learnings from the INBUILD trial in patients with progressive pulmonary fibrosis[J].Ther Adv Respir Dis,2024,18:17534666241266343. [60] Kim M J,Yang J,Song J W.Acute exacerbation of progressive pulmonary fibrosis:Incidence and outcomes[J].Respir Res,2024,25(1):415. [61] Solomon J J,Chung J H,Cosgrove G P,et al.Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease[J].Eur Respir J,2016,47(2):588-596. [62] Fan J J,Gu J M,Xiao S Y,et al.Risk factors for progression of pulmonary fibrosis:A single-centered,retrospective study[J].Front Med,2024,11:1335758. [63] Lee S M,Seo J B,Oh S Y,et al.Prediction of survival by texture-based automated quantitative assessment of regional disease patterns on CT in idiopathic pulmonary fibrosis[J].Eur Radiol,2018,28(3):1293-1300. [64] Chen Y H,Lee T J,Hsieh H J,et al.Clinical outcomes and risk factors of progressive pulmonary fibrosis in primary Sjögren’s syndrome-associated interstitial lung disease[J].BMC Pulm Med,2023,23(1):268. [65] Hambly N,Farooqi M M,Dvorkin-Gheva A,et al.Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry[J].Eur Respir J,2022,60(4):2102571. [66] Choi B,Kawut S M,Raghu G,et al.Regional distribution of high-attenuation areas on chest computed tomography in the Multi-Ethnic Study of Atherosclerosis[J].ERJ Open Res,2020,6(1):00115-02019. [67] Barnes H,Humphries S M,George P M,et al.Machine learning in radiology:The new frontier in interstitial lung diseases[J].Lancet Digit Heal,2023,5(1):e41-e50. [68] Guiot J,Henket M,Gester F,et al.Automated AI-based image analysis for quantification and prediction of interstitial lung disease in systemic sclerosis patients[J].Respir Res,2025,26(1):39. [69] Chelala L,Brixey A G,Hobbs S B,et al.Current state of fibrotic interstitial lung disease imaging[J].Radiology,2025,316:e242531. [70] Zhu W,Liu C,Tan C,et al.Predictive biomarkers of disease progression in idiopathic pulmonary fibrosis[J].Heliyon,2024,10(1):e23543. [71] Li X,Lin Q,Guan B,et al.Multi-omics analysis links mitochondrial-related genes to idiopathic pulmonary fibrosis and in vivo transcriptome validation[J].Transl Res,2025,278:10-21. [72] Karampitsakos T,Jia M,Tourki B,et al.The transcriptome of CD14+CD163-HLA-DRlow monocytes predicts mortality in idiopathic pulmonary fibrosis[J].Eur Respir J,2026,67(5):2500804. [73] Zhumagaliyeva A,Chorostowska-Wynimko J,Jezela-Stanek A.Genetic determinants of progressive pulmonary fibrosis:A comprehensive review[J].Int J Mol Sci,2025,26(24):11846. [74] Wollin L,Wex E,Pautsch A,et al.Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis[J].Eur Respir J,2015,45(5):1434-1445. [75] Flaherty K R,Wells A U,Cottin V,et al.Nintedanib in progressive fibrosing interstitial lung diseases[J].N Engl J Med,2019,381(18):1718-1727. [76] Au W,Kr F,Kk B,et al.Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial:A randomised,double-blind,placebo-controlled,parallel-group trial[J].Lancet Respir Med,2020,8(5):453-460. [77] Distler O,Highland K B,Gahlemann M,et al.Nintedanib for systemic sclerosis-associated interstitial lung disease[J].N Engl J Med,2019,380(26):2518-2528. [78] Dixon G,Hague S,Mulholland S,et al.Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK[J].ERJ Open Res,2024,10(1):00529-2023. [79] Ocal N,Cilli A,Mogulkoc N,et al.Analysis of treatment efficacy,tolerability,and survival of patients receiving antifibrotic therapy for progressive nonidiopathic pulmonary fibrosis[J].Ann Thorac Med,2025,20(2):98-107. [80] Mondoni M,Varone F,Luppi F,et al.Effectiveness of nintedanib in progressive pulmonary fibrosis assessed by progression criteria:An Italian,observational,multicenter study[J].Lung,2025,203(1):77. [81] Chianese M,Screm G,Salton F,et al.Pirfenidone and nintedanib in pulmonary fibrosis:Lights and shadows[J].Pharmaceuticals,2024,17(6):709. [82] Bargagli E,Piccioli C,Rosi E,et al.Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis:Real-life experience in an Italian referral centre[J].Pulmonology,2019,25(3):149-153. [83] Westerink L,Nicolai J L J,Postma M J,et al.Cost-eff-ectiveness of nintedanib for patients with progressive fibrosing interstitial lung disease (PF-ILD)[J].Pharmacoecon Open,2022,6(5):647-656. [84] Chaudhuri N,Azuma A,Sroka-Saidi K,et al.Safety and tolerability of nintedanib in patients with fibrosing interstitial lung diseases:Post-marketing data[J].Adv Ther,2024,41(12):4581-4590. [85] Lv Q,Wang J,Xu C,et al.Pirfenidone alleviates pulmonary fibrosis [86] Ruwanpura S M,Thomas B J,Bardin P G.Pirfenidone:Molecular mechanisms and potential clinical applications in lung disease[J].Am J Respir Cell Mol Biol,2020,62(4):413-422. [87] Maher T M,Corte T J,Fischer A,et al.Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease:A double-blind,randomised,placebo-controlled,phase 2 trial[J].Lancet Respir Med,2020,8(2):147-157. [88] Behr J,Prasse A,Kreuter M,et al.Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF):A double-blind,randomised,placebo-controlled,phase 2b trial[J].Lancet Respir Med,2021,9(5):476-486. [89] Nieto M A,Vadillo C,Pernaute O S,et al.Role of antifibrotics in progressive pulmonary fibrosis associated to autoimmune diseases:Multicenter study from NEREA registry[J].Respir Res,2025,26(1):234. [90] Aimo A,Spitaleri G,Nieri D,et al.Pirfenidone for idiopathic pulmonary fibrosis and beyond[J].Card Fail Rev,2022,8:e12. [91] 中华人民共和国国家卫生健康委员会.国家卫生健康委办公厅关于印发软骨发育不全等86个罕见病病种诊疗指南(2025年版)的通知[EB/OL].(2025-07-10)[2026-01-07].https://www.nhc.gov.cn/yzygj/c100068/202507/5b3f41180a42465eb9eec34597bacaf2.shtml [92] Li H,Zuo J,Tang W.Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases[J].Front Pharmacol,2018,9:1048. [93] Kolb M,Crestani B,Maher T M.Phosphodiesterase 4B inhibition:A potential novel strategy for treating pulmonary fibrosis[J].Eur Respir Rev,2023,32(167):220206. [94] Matsuhira T,Nishiyama O,Tabata Y,et al.A novel phosphodiesterase 4 inhibitor,AA6216,reduces macrophage activity and fibrosis in the lung[J].Eur J Pharmacol,2020,885:173508. [95] Sisson T H,Christensen P J,Muraki Y,et al.Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury[J].Physiol Rep,2018,6(12):e13753. [96] Jin S L,Goya S,Nakae S,et al.Phosphodiesterase 4B is essential for T(H)2-cell function and development of airway hyperresponsiveness in allergic asthma[J].J Allergy Clin Immunol,2010,126(6):1252-1259.e12. [97] Hansen G,Jin S,Umetsu D T,et al.Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D[J].Proc Natl Acad Sci U S A,2000,97(12):6751-6756. [98] Selige J,Hatzelmann A,Dunkern T.The differential impact of PDE4 subtypes in human lung fibroblasts on cytokine-induced proliferation and myofibroblast conversion[J].J Cell Physiol,2011,226(8):1970-1980. [99] Herrmann F,Hesslinger C,Wollin L,et al.BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis[J].Front Pharmacol,2022,13:838449. [100] Maher T M,Assassi S,Azuma A,et al.Nerandomilast in patients with progressive pulmonary fibrosis[J].N Engl J Med,2025,392(22):2203-2214. [101] Decaris M L,Schaub J R,Chen C,et al.Dual inhibition of αvβ6 and αvβ1 reduces fibrogenesis in lung tissue explants from patients with IPF[J].Respir Res,2021,22(1):265. [102] Lancaster L,Cottin V,Ramaswamy M,et al.Bexotegrast in patients with idiopathic pulmonary fibrosis:The INTEGRIS-IPF clinical trial[J].Am J Respir Crit Care Med,2024,210(4):424-434. [103] Montesi S B,Cosgrove G P,Turner S M,et al.Dual αvβ6 and αvβ1 inhibition over 12 weeks reduces active type I collagen deposition in individuals with idiopathic pulmonary fibrosis:A phase 2,double-blind,placebo-controlled clinical trial[J].Am J Respir Crit Care Med,2025,211(7):1229-1240. [104] Denis A,Tsiri P,Guiot J,et al.A new era in the treatment of progressive fibrosing interstitial lung diseases[J].Breathe (Sheff),2025,21(2):240259. [105] Shea B S,Tager A M.Role of the lysophospholipid mediators lysophosphatidic acid and sphingosine 1-phosphate in lung fibrosis[J].Proc Am Thorac Soc,2012,9(3):102-110. [106] Corte T J,Behr J,Cottin V,et al.Efficacy and safety of admilparant,an LPA1 antagonist,in pulmonary fibrosis:A phase 2 randomized clinical trial[J].Am J Respir Crit Care Med,2025,211(2):230-238. [107] Kolb M,Orfanos S E,Lambers C,et al.The antifibrotic effects of inhaled treprostinil:An emerging option for ILD[J].Adv Ther,2022,39(9):3881-3895. [108] Nikitopoulou I,Manitsopoulos N,Kotanidou A,et al.Orotracheal treprostinil administration attenuates bleomycin-induced lung injury,vascular remodeling,and fibrosis in mice[J].Pulm Circ,2019,9(4):2045894019881954. [109] Fang L,Chen W C,Jaksch P,et al.Treprostinil reconstitutes mitochondrial organisation and structure in idiopathic pulmonary fibrosis cells[J].Int J Mol Sci,2023,24(15):12148. [110] Lambers C,Roth M,Jaksch P,et al.Treprostinil inhibits proliferation and extracellular matrix deposition by fibroblasts through cAMP activation[J].Sci Rep,2018,8(1):1087. [111] Kolodsick J E,Peters-Golden M,Larios J,et al.Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E.Prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation[J].Am J Respir Cell Mol Biol,2003,29(5):537-544. [112] Ayabe S,Kida T,Hori M,et al.Prostaglandin D2 inhibits collagen secretion from lung fibroblasts by activating the DP receptor[J].J Pharmacol Sci,2013,121(4):312-317. [113] White E S,Atrasz R G,Dickie E G,et al.Prostaglandin E(2) inhibits fibroblast migration by E-prostanoid 2 receptor-mediated increase in PTEN activity[J].Am J Respir Cell Mol Biol,2005,32(2):135-141. [114] Ali F Y,Egan K,FitzGerald G A,et al.Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts[J].Am J Respir Cell Mol Biol,2006,34(2):242-246. [115] Nathan S D,Waxman A,Rajagopal S,et al.Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension:A post-hoc analysis of the INCREASE study[J].Lancet Respir Med,2021,9(11):1266-1274. [116] Effendi W I,Nagano T.The hedgehog signaling pathway in idiopathic pulmonary fibrosis:Resurrection time[J].Int J Mol Sci,2021,23(1):171. [117] Maher T M,Goldin J G,Hood J,et al.Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101):A multicentre,randomised,double-blind,placebo-controlled,phase 2a trial[J].Lancet Respir Med,2025,13(11):1001-1010. [118] Huang H,Wang Q,Xu Z.Advances in the identification and management of progressive pulmonary fibrosis:Perspective from Chinese experts[J].Ther Adv Respir Dis,2024,18:17534666241288417. [119] Tashkin D P,Elashoff R,Clements P J,et al.Cyclophosphamide versus placebo in scleroderma lung disease[J].N Engl J Med,2006,354(25):2655-2666. [120] Tashkin D P,Roth M D,Clements P J,et al.Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS Ⅱ):A randomised controlled,double-blind,parallel group trial[J].Lancet Respir Med,2016,4(9):708-719. [121] Johnson S R,Bernstein E J,Bolster M B,et al.2023 American college of rheumatology (ACR)/American college of chest physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases[J].Arthritis Rheumatol,2024,76(8):1182-1200. [122] Calaras D,David A,Vasarmidi E,et al.Hypersensitivity pneumonitis:Challenges of a complex disease[J].Can Respir J,2024,2024(1):4919951. [123] Morisset J,Johannson K A,Vittinghoff E,et al.Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis[J].Chest,2017,151(3):619-625. [124] Adegunsoye A,Oldham J M,Fernández Pérez E R,et al.Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis[J].ERJ Open Res,2017,3(3):00016-02017. [125] Kang H K,Song J W.Progressive pulmonary fibrosis:Where are we now?[J].Tuberc Respir Dis,2024,87(2):123-133. [126] Kreuter M,Belloli E A,Bendstrup E,et al.Acute exacerbations in patients with progressive pulmonary fibrosis[J].ERJ Open Res,2024,10(6):00403-02024. [127] Rajan S K,Cottin V,Dhar R,et al.Progressive pulmonary fibrosis:An expert group consensus statement[J].Eur Respir J,2023,61(3):2103187. [128] Nici L,Donner C,Wouters E,et al.American thoracic society/European respiratory society statement on pulmonary rehabilitation[J].Am J Respir Crit Care Med,2006,173(12):1390-1413. [129] Jacobs S S,Krishnan J A,Lederer D J,et al.Home oxygen therapy for adults with chronic lung disease.An official American thoracic society clinical practice guideline[J].Am J Respir Crit Care Med,2020,202(10):e121-e141. [130] Oliveira A,Fabbri G,Gille T,et al.Holistic management of patients with progressive pulmonary fibrosis[J].Breathe (Sheff),2023,19(3):230101. |
| [1] | 王丹丹, 任彬彬△. 脊髓损伤后神经病理性疼痛发病机制及神经调控技术治疗研究进展[J]. 华中科技大学学报（医学版）, 2025, 54(6): 916-923. |
| [2] | 扈晓芳, 欧阳沙西. 有氧糖酵解在糖尿病肾病中的作用研究进展[J]. 华中科技大学学报（医学版）, 2025, 54(4): 593-597. |
| [3] | 院一蔚, 叶子丰, 张 乐, 欧 梁, 匡建军. 中性粒细胞胞外诱捕网在炎症性关节疾病中的研究进展[J]. 华中科技大学学报（医学版）, 2025, 54(3): 428-432. |
| [4] | 曹 杰, 袁 莉. 不同组织来源的外泌体在非酒精性脂肪性肝病发展中的作用[J]. 华中科技大学学报（医学版）, 2024, 53(2): 256-261. |
| [5] | 曹 理, 吴 蔚, 景豆豆, 郭昊宇, 浦飞飞, 邵增务. 骨巨细胞瘤发病现状及驱动 RANKL/OPG 失衡机制的研究进展[J]. 华中科技大学学报（医学版）, 2022, 51(5): 700-705. |
| [6] | 刘智霖, 马建岭, 史利卿, 王 颖, 王丽云, 李扭扭, 季 坤, 董尚娟, 温绍惠. 难治性慢性咳嗽发病机制及治疗的研究进展[J]. 华中科技大学学报（医学版）, 2022, 51(4): 578-583. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
